Skip to main content
Account

Peer review reports

From: Responsiveness and construct validity of EPIC-26, AQoL-6D and SF-6D following treatment in prostate cancer

Original Submission
27 Aug 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
30 Nov 2022 Reviewed Reviewer Report
1 Dec 2022 Reviewed Reviewer Report - Eleni Stamatopoulou
13 Dec 2022 Reviewed Reviewer Report
13 Feb 2023 Author responded Author comments - Norma B. Bulamu
Resubmission - Version 3
13 Feb 2023 Submitted Manuscript version 3
14 Feb 2023 Author responded Author comments - Norma B. Bulamu
Resubmission - Version 4
14 Feb 2023 Submitted Manuscript version 4
Publishing
13 Mar 2023 Editorially accepted
1 Apr 2023 Article published 10.1186/s12885-023-10732-6

Learn about peer review

Back to article page

Navigation